DaVita (DVA) stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 64 to 72.
↑ XThis exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an RS Rating north of 80 in the early stages of their moves. See if DaVita stock can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Davita stock is currently trading below its 50-day moving average. While the stock is not near an ideal buying range right now, see if it goes on to form and break out from a proper base.
The kidney dialysis center operator reported -12% earnings growth in the latest quarterly report. Sales rose 5%.
Davita stock earns the No. 8 rank among its peers in the Medical-Outpatient/Home Care industry group. Addus HomeCare (ADUS), Encompass Health (EHC) and RadNet (RDNT) are among the top 5 highly rated stocks within the group.
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。